BioCentury | Jun 16, 2014
Clinical News

Jublia efinaconazole regulatory update

...Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said FDA approved an NDA for Jublia efinaconazole...
...indication. In the U.S., the wholesale acquisition cost (WAC) for a 4 mL bottle of Jublia...
...20, 2013). Kaken Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Jublia efinaconazole ( KP-103 , IDP-108...
BioCentury | Nov 11, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious, dermatology news

...services to help Anacor develop its topical antifungal agent, tavaborole. Valeant -- which is developing efinaconazole...
...with a July 29, 2014, PDUFA date. In May, Valeant said it would not launch efinaconazole...
...response letter from FDA for Jublia efinaconazole to treat onychomycosis. In October, Health Canada approved Jublia...
BioCentury | Oct 21, 2013
Finance

Highlights of weekly biotech stock moves

...services to help Anacor develop its topical antifungal agent tavaborole. Valeant - which is developing efinaconazole...
BioCentury | Oct 21, 2013
Company News

Anacor, Valeant Pharmaceuticals infectious news

...services to help Anacor develop its topical antifungal agent tavaborole. Valeant - which is developing efinaconazole...
...for onychomycosis, with a July 29, 2014, PDUFA date. In May, Valeant would not launch efinaconazole...
...letter from FDA for Jublia efinaconazole to treat onychomycosis. Earlier this month, Health Canada approved Jublia...
BioCentury | Oct 19, 2013
Company News

Anacor jumps on damages award in contract dispute

...services to help Anacor develop its topical antifungal agent tavaborole. Valeant -- which is developing efinaconazole...
...29, 2014, PDUFA date. In May, Valeant received a complete response letter from FDA for efinaconazole...
BioCentury | Oct 7, 2013
Clinical News

Jublia efinaconazole regulatory update

...Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said Health Canada approved an NDS for Jublia efinaconazole...
...triazole antifungal. Valeant has worldwide commercialization rights, excluding Japan, China, Taiwan and South Korea, to efinaconazole...
...May 20). Kaken Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Jublia efinaconazole ( IDP-108 , KP-103...
BioCentury | Jun 3, 2013
Clinical News

Efinaconazole regulatory update

...Mississauga, Ontario) said it received a complete response letter from FDA for an NDA for efinaconazole...
...to the topical triazole antifungal from Kaken. In May, Valeant said it will not launch efinaconazole...
...BioCentury, May 20). Kaken Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Efinaconazole ( IDP-108 , KP-103...
BioCentury | May 20, 2013
Company News

Anacor, Valeant Pharmaceuticals sales and marketing update

...Valeant said it will not launch efinaconazole to treat onychomycosis until after its September arbitration hearing...
...services in connection with Anacor's development of its topical antifungal agent tavaborole, a competitor to efinaconazole...
...could not be reached (see BioCentury, Dec. 15, 2008). Due to the delay in the efinaconazole...
BioCentury | Apr 1, 2013
Finance

2Q13 Financial Markets Preview: Manning the middle

...Ph III ESTABLISH 2 data April Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX)/Kaken Pharmaceutical Co. Ltd. Efinaconazole...
BioCentury | Feb 4, 2013
Finance

Highlights of weekly biotech stock moves

...vs. 0.5%, p=0.001) (see B17) . Late last year, Kaken Pharmaceutical Co. Ltd. reported that efinaconazole...
...controls in a pair of Phase III trials (17.8% vs. 3.3% and 15.2% vs. 5.5%). Efinaconazole...
Items per page:
1 - 10 of 15